3652 results for «239»
3652 results
News from drug-eluting therapies in 2026
19 May 2026 – From EuroPCR 2026
This session presents the latest advancements in drug-eluting therapies for 2026, including predictors of target lesion failure after drug-coated balloon treatment, clinical outcomes related to stenting length, and novel insights into sirolimus transfer evidenced by in vivo OCT imaging.
TAVI complications: impact and improvement
20 May 2026 – From EuroPCR 2026
This session examines critical complications associated with TAVI and strategies to mitigate their impact. Topics include carbon-dioxide flushing to reduce brain injury, management of cardiac tamponade, AI-driven customization of TAVI in complex anatomies, and the influence of vascular complications on post-procedural quality of life.
INOCA/ANOCA: technical aspects
20 May 2026 – From EuroPCR 2026
This session covers technical aspects critical to the evaluation and management of ischemia with non-obstructive coronary arteries (INOCA) and angina with non-obstructive coronary arteries (ANOCA). Key topics include the impact of guide catheter shape, injection techniques for thermodilution measurements, advanced perfusion CMR diagnostics, and the physiological...
FFR and non-hyperaemic pressure ratios
20 May 2026 – From EuroPCR 2026
This session presents contemporary clinical applications of fractional flow reserve (FFR) and non-hyperaemic pressure ratios (NHPR), highlighting real-world impacts of physiology microcatheter-based indices, the interplay between epicardial stenosis and microvascular resistance, post-PCI hyperemia effects on iFR, and machine-learning driven outcome predictions.
Other right-sided and tricuspid valve interventions
20 May 2026 – From EuroPCR 2026
This session focuses on right-sided heart valve interventions, particularly targeting tricuspid valve disease. Topics include clinical outcomes in atrial functional tricuspid regurgitation, management in the context of left-sided valvular disease, treatment approaches for tricuspid valve endocarditis, and advances in transcatheter therapies and device placements.
Insights from real world TAVI practice
20 May 2026 – From EuroPCR 2026
This session presents comprehensive insights from real-world transcatheter aortic valve implantation (TAVI) practice, including sex differences in coronary assessment, the impact of general anesthesia on aortic valve gradients, early rehospitalisation rates, and the management of TAVI in patients with prior hip arthroplasty. Additionally, it explores multinational...
Continual refinement in LAA closure
20 May 2026 – From EuroPCR 2026
This session presents the latest advancements in left atrial appendage closure (LAAC). It covers new risk scoring systems, sex-specific outcome analyses, safety in elderly populations, and comparative data between LAMBRE and WATCHMAN devices from a high-volume center, highlighting continual refinement in LAAC strategies.
Aortic stenosis: from diagnostic to treatment
21 May 2026 – From EuroPCR 2026
This session provides an in-depth review of contemporary management of aortic stenosis, covering diagnostic advancements, temporal trends, and treatment outcomes. It includes insights from the LAPLACE-TAVI registry focusing on low-risk patients, discusses the growing feasibility of day-case TAVI procedures, compares transcatheter and surgical valve replacements in...
News regarding the SIRONA Randomized Trial
10 Feb 2022
EuroPCR 2024: Primary outcomes from PINNACLE I clinical trial establish safety and effectiveness of Elixir Medical’s Hertz Contact Intravascular Lithotripsy System for calcium fragmentation in moderate to severe calcified coronary artery lesions
16 May 2024
TRILUMINATE pivotal: A landmark randomized clinical trial of transcatheter tricuspid valve edge-to-edge repair for tricuspid regurgitation
04 Mar 2023
Jonathan Curio and Alex Sticchi provide their take on this clinical trial which was presented by Paul Sorajja at the American College of Cardiology Scientific Session (ACC.23/WCC).
Author
Author
BioCardia reports positive interim results from phase III CardiAMP cell therapy heart failure trial, with compelling data in subgroup with elevated NTproBNP biomarker for heart failure.
04 Mar 2024